Baird Financial Group Inc. decreased its position in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 34.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,832 shares of the medical instruments supplier's stock after selling 26,905 shares during the period. Baird Financial Group Inc.'s holdings in Baxter International were worth $1,740,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new position in Baxter International during the 1st quarter worth $27,000. Rossby Financial LCC acquired a new position in Baxter International during the 1st quarter worth $29,000. MassMutual Private Wealth & Trust FSB lifted its position in Baxter International by 48.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 656 shares during the last quarter. Archer Investment Corp lifted its position in Baxter International by 20.5% during the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier's stock worth $100,000 after acquiring an additional 500 shares during the last quarter. Finally, Bruce G. Allen Investments LLC lifted its position in Baxter International by 35.2% during the 1st quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier's stock worth $121,000 after acquiring an additional 924 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. Stifel Nicolaus restated a "hold" rating and set a $25.00 price objective (down previously from $36.00) on shares of Baxter International in a report on Monday, August 4th. The Goldman Sachs Group downgraded shares of Baxter International from a "buy" rating to a "neutral" rating and set a $25.00 price objective on the stock. in a report on Friday, August 1st. Evercore ISI dropped their price objective on shares of Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Wall Street Zen downgraded shares of Baxter International from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, Morgan Stanley dropped their price objective on shares of Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a report on Tuesday, July 15th. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Baxter International currently has a consensus rating of "Hold" and an average price target of $30.11.
Read Our Latest Report on Baxter International
Baxter International Stock Performance
NYSE BAX opened at $24.42 on Monday. The stock has a market cap of $12.54 billion, a P/E ratio of -81.38, a PEG ratio of 0.80 and a beta of 0.60. The company's 50-day simple moving average is $26.28 and its 200 day simple moving average is $29.69. Baxter International Inc. has a twelve month low of $21.33 and a twelve month high of $40.49. The company has a quick ratio of 1.49, a current ratio of 2.30 and a debt-to-equity ratio of 1.30.
Baxter International (NYSE:BAX - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). The business had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business's revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.68 EPS. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. As a group, research analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.
Baxter International Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 dividend on an annualized basis and a yield of 2.8%. Baxter International's payout ratio is presently -226.67%.
About Baxter International
(
Free Report)
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Further Reading
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
